Peter Eu

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

Medicine, Nuclear Medicine, Oncology +14

Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 486 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani et al. · Journal of Nuclear Medicine · 2019 · 286 citations · Full text

Medicine, Oncology, Pharmacology +17

High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours

Michael S. Hofman, Grace Kong, Oliver Neels et al. · Journal of Medical Imaging and Radiation Oncology · 2012 · 252 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI

J Lodhia, Giovanni Mandarano, NJ Ferris et al. · Biomedical Imaging and Intervention Journal · 2010 · 209 citations · Full text

Medicine, Oncology, Radiation Oncology +17